Get the latest tech news
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
Yeztugo (generic name lenacapavir), which is given by health care workers in clinics, is significantly more effective than the existing oral HIV-prevention drugs, experts said, because it appears to address the challenges of sticking to a daily pill regimen for people who are at high risk of HIV. Despite being much more effective than Truvada at lowering HIV cases across a population of gay and bisexual men and transgender women in a major clinical trial, Apretude has gained scant traction until recently. Tristan Schukraft, CEO of the popular PrEP-focused telehealth company Mistr, said it intends to begin offering the drug immediately through its storefronts in seven major urban gay neighborhoods.
Or read this on r/technology
